

Attorney Docket No.: 6225.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Koch et al

Serial No.: 10/016,858

Group Art Unit: 1617

Filed: December 14, 2001

Examiner: Hui, San Ming R.

For: Hormone Composition

RECEIVED
CENTRAL FAX CENTER

OCT 17 2003

CERTIFICATE OF FACSIMILE TRANSMISSION

OFFICIAL

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:


I hereby certify that the attached correspondence comprising:

1. Supplemental Information Disclosure Statement
2. Form PTO-1449
3. Copy of References (3)

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner Hui, San Ming R., fax number (703) 872-9306.

Respectfully submitted,

Date: October 16, 2003



Dolly Kapadia
Novo Nordisk® Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Attorney Docket No.: 6225.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Koch et al

Application No.: 10/016,858

Group Art Unit: 1617

Filed: December 14, 2001

Examiner: Hui, San Ming R.

For: Hormone Composition

RECEIVED
CENTRAL FAX CENTER

OCT 17 2003

OFFICIAL

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENTCommissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. Kvorning et al., Saldioe and Eriksen, Editors, The Urogenital Oestrogen Deficiency Syndrome, Proceedings of the International Workshop, Copenhagen, pages 51-60 (1986)
2. Nilsson et al., Maturitas, Vol. 15, pages 121-127 (1992)
3. Dugal et al., Acta Obstet. Gynecol. Scan., Vol. 79, pages 293-297 (2000)

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.


This information disclosure statement is being filed after the period set forth in 37 C.F.R. 1.97(b), but before the mailing date of any of a final action, a notice of allowance, or an action that otherwise closes prosecution.

Accompanying this information disclosure statement is

☒ the fee set forth in 37 C.F.R. § 1.17(p) (currently \$180.00). Charge Deposit Account No. 14-1447 in the amount of \$180.00. A duplicate of this charge directive is attached.

Date: October 16, 2003

Respectfully submitted,



Reza Green, Reg. No. 38,475
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

23650

PATENT TRADEMARK OFFICE

OFFICIAL

**RECEIVED
CENTRAL FAX CENTER**

OCT 17 2003

